Document Type : Original Article
Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Isfahan Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Iranian Multiple Sclerosis and Neuroimmunology Research Center, Isfahan, Iran
Objective: The function of Th17 cells in the neuroinflammatory process in multiple sclerosis (MS) has been previously
clarified. It has been suggested that Quercetin can influence MS due to a variety of anti-inflammatory effects. The present
study aimed to examine in vitro immunomodulatory aspects of Quercetin Penta Acetate as a modified compound on
Th17 cells of MS patients and also to compare its effects with Quercetin.
Materials and Methods: In this experimental study, peripheral blood mononuclear cell (PBMCs) were isolated and
stained with CFSE then, half-maximal inhibitory concentration (IC50) values were determined using different doses
and times for Quercetin Penta Acetate, and Methyl Prednisolone Acetate. Th17 cell proliferation was analyzed by flow
cytometry and the expression levels of IL-17 and RORc genes were assessed by real-time polymerase chain reaction
Results: The results showed that IL-17A gene expression was inhibited by Quercetin Penta Acetate (P=0.0081), but
Quercetin Penta Acetate did not have a significant inhibitory effect on Th17 cells proliferation (P= 0.59) and RORc gene
expression (P=0.1), compared to Quercetin.
Conclusion: Taken together, our results showed some immunomodulatory aspects of Quercetin Penta Acetate on
Th17 cells are more effective than Quercetin and it could be considered in the treatment of MS.